Disclaimer

The alfapump® system is not currently approved in the United States or Canada. In the United States and Canada, the alfapump® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. For more information regarding the POSEIDON clinical study see www.poseidonstudy.com.
The DSR therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed.
The DSR therapy is not currently approved for clinical research in the United States or Canada. There is no link between the DSR therapy and ongoing investigations with the alfapump® system in Europe.

Press releases

Sequana Medical announces positive interim data from North American pivotal alfapump® study (POSEIDON)

REGULATED INFORMATION – INSIDE INFORMATION 19 November 2020, 08:00 am CET   Results from first 13 patients in Roll-In Cohort showed over 90% reduction in mean frequency of therapeutic paracentesis versus baseline Indication of rapid and persistent clinically relevant improvement in patients’ quality of life Safety profile in line with expectations Interim data of the...

Sequana Medical to present at Jefferies 2020 Virtual London Healthcare Conference

Ghent, BELGIUM – 12 November 2020 – Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces that Ian Crosbie, Chief Executive Officer, will present at the Jefferies 2020 Virtual London Healthcare Conference taking place from 17 to 19 November 2020....

Sequana Medical announces strong interim results from RED DESERT alfapump® DSR study and provides business update

PRESS RELEASE REGULATED INFORMATION – INSIDE INFORMATION 22 October 2020, 07:00am CET   RED DESERT: Results from first five patients indicate repeated dose alfapump DSR therapy to be safe and effective Interim data support DSR hypothesis: kidneys eliminate free water to maintain patients’ serum sodium levels No patients required loop diuretic therapy during the six-week...

Sequana Medical appoints two additional experts as Heart Failure Scientific Advisors

Dr. Felker and Dr. Udelson join current advisors to support the development of alfapump® DSR for the management of fluid overload in patients with heart failure   Ghent, BELGIUM – 15 October 2020 – Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the management of fluid overload in liver disease, malignant ascites and heart...

Sequana Medical announces September 2020 Investor Conference Schedule

Ghent, BELGIUM – 09 September 2020 – Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces that it will participate in two virtual investor events in September 2020.   H.C. Wainwright & Co 22nd Annual Global Investment Conference, 14-16 September...

Sequana Medical announces H1 2020 results and provides business update

PRESS RELEASE REGULATED INFORMATION – INSIDE INFORMATION 03 September 2020, 07:00 CEST   POSEIDON – Implants in Canada continue; interim results expected H1 2021 RED DESERT – Implants continue; interim results expected Q4 2020 DSR (Direct Sodium Removal) – Fundamental patents allowed in U.S. and Europe Continued growth in European commercial implants Secured additional funding...

Sequana Medical Notice of 2020 Half Year Results and Business Update

Ghent, BELGIUM – 27 August 2020 – Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, will announce its results for the half year ended 30 June 2020 on Thursday, 3 September 2020. The management team will host a conference call with...

Sequana Medical announces €7.3 million debt financing and provides clinical update

REGULATED INFORMATION – INSIDE INFORMATION 28 July 2020, 07:00 CEST  Cash runway extended into H2 2021 enabling Sequana Medical to reach key near term value inflection points POSEIDON – implants resumed and interim results expected in Q1 2021 (North American pivotal study of the alfapump® in patients with recurrent or refractory ascites due to liver...

Sequana Medical to present at digital Investor Events

Ghent, BELGIUM – 17 June 2020 – Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces that Ian Crosbie, Chief Executive Officer, will present at the following digital investor events in June:   Kepler Cheuvreux Digital Belgian Life Science Day...

Sequana Medical announces that the results of the alfapump® MOSAIC study have been published in Liver Transplantation  

North American feasibility study demonstrated the utility, safety and efficacy of the alfapump in the management of patients with recurrent and refractory ascites   Ghent, BELGIUM – 16 June 2020 – Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces...
1 2 3 6

Subscribe to our Press Releases

I agree to the Sequana Medical Privacy Policy

We would like to use cookies to better understand your use of this website. This enables us to improve your future experience on our website. Detailed information about the use of cookies on this website and how you can manage or withdraw your consent at any time can be found in our. Privacy & Cookie Policy

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close